Halozyme posts record Q3 2026 revenue of $493 million, up 39% year over year
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. Total Revenue: $493 million, up 39% year over year from $354.3 million. Royalty Revenue: Record $341 million, up 44% year over year. DARZALEX Royalty Revenue: $153.5 million, up 20% year over year. VYVGART Royalty Revenue: $88.1 million…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRecord royalty revenue and strong net income growth are relevant for HALO shares and its pharma partners.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Total revenue was $493 million, up 39% year over year.
- 02Royalty revenue hit a record $341 million, up 44% year over year.
- 03Net income was $247 million, up 41% from the prior year.
- 04SG&A expenses included consulting fees tied to Merck litigation costs.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Halozyme Therapeutics, Inc.122.96 USDMarket closedtoday -5.66%Positive Merck & Co., Inc.146.94 USDMarket closedtoday -2.27%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets